CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs

Rhea-AI Filing Summary

Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.

Beam Therapeutics reported that its Chief Financial Officer, Sravan Kumar Emany, received a grant of 31,750 shares of common stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in four substantially equal annual installments, starting on the first anniversary of the grant date, if he continues serving at the company. Following this award, his directly held common stock position is 105,456 shares, reflecting compensation tied to long-term service and company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Emany Sravan Kumar

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	31,750	$0.00	--

Holdings After Transaction: Common Stock — 105,456 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 31,750 shares Post-grant holdings: 105,456 shares Vesting schedule: 4 installments +1 more

4 metrics

RSU grant size 31,750 shares Restricted stock units granted to CFO on the reported date

Post-grant holdings 105,456 shares Total common stock directly held by CFO after transaction

Vesting schedule 4 installments RSUs vest in four substantially equal annual installments

Grant price $0.0000 per share Reported transaction price per RSU share

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, contingent right to receive, vest in four substantially equal installments

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

contingent right to receive financial

"Each RSU represents the contingent right to receive one share of BEAM's common stock"

vest in four substantially equal installments financial

"The RSUs vest in four substantially equal installments on each of the first four anniversaries"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Emany Sravan Kumar

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		31,750(1)	A	$0	105,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beam Therapeutics (BEAM) report for its CFO?

Beam Therapeutics reported that CFO Sravan Kumar Emany received 31,750 restricted stock units. The award was granted under the 2019 Equity Incentive Plan and represents additional equity-based compensation rather than a market purchase of shares.

How many Beam Therapeutics shares does the CFO hold after this Form 4?

After the reported grant, CFO Sravan Kumar Emany directly holds 105,456 shares of Beam Therapeutics common stock. This total includes the newly awarded restricted stock units, which convert into shares as they vest over time.

What are the terms of the 31,750 RSU grant to Beam Therapeutics’ CFO?

The 31,750 restricted stock units vest in four substantially equal installments on each of the first four anniversaries of the grant date. Vesting requires the CFO’s continued service with Beam Therapeutics through each applicable vesting date.

Did the Beam Therapeutics CFO pay a price per share for these RSUs?

No cash price was paid for these restricted stock units; the Form 4 shows a per-share transaction price of 0.0000. The RSUs are equity compensation that convert into common shares upon vesting, subject to continued service conditions.

What does each Beam Therapeutics RSU granted to the CFO represent?

Each restricted stock unit granted to the CFO represents a contingent right to receive one share of Beam Therapeutics common stock. Delivery of shares occurs as the RSUs vest over time under the company’s 2019 Equity Incentive Plan.